CMG Pharmaceutical Co. Ltd (058820) — Cash Flow-to-Debt Ratio
CMG Pharmaceutical Co. Ltd (058820) has a Cash Flow-to-Debt Ratio of -0.04x as of December 2025, meaning its operating cash flow of ₩-4.08 Billion could theoretically repay 0% of its total liabilities (₩104.41 Billion) in one year. Explore CMG Pharmaceutical Co. Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CMG Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for CMG Pharmaceutical Co. Ltd across 12 annual periods. Also explore CMG Pharmaceutical Co. Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CMG Pharmaceutical Co. Ltd (2014–2025)
Year-by-year debt coverage analysis for CMG Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see 058820 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | ₩-11.02 Billion | ₩104.41 Billion | ▼ -4244.1% |
| 2024 | 0.00x | ₩290.09 Million | ₩113.89 Billion | ▼ -96.6% |
| 2023 | 0.08x | ₩3.91 Billion | ₩51.87 Billion | ▼ -56.8% |
| 2022 | 0.17x | ₩4.94 Billion | ₩28.31 Billion | ▼ -55.2% |
| 2021 | 0.39x | ₩5.63 Billion | ₩14.47 Billion | ▲ +87.9% |
| 2020 | 0.21x | ₩2.94 Billion | ₩14.22 Billion | ▼ -11.4% |
| 2019 | 0.23x | ₩2.82 Billion | ₩12.08 Billion | ▲ +173.9% |
| 2018 | 0.09x | ₩886.78 Million | ₩10.40 Billion | ▼ -49.1% |
| 2017 | 0.17x | ₩1.95 Billion | ₩11.62 Billion | ▼ -28.3% |
| 2016 | 0.23x | ₩2.31 Billion | ₩9.87 Billion | ▼ -5.7% |
| 2015 | 0.25x | ₩2.41 Billion | ₩9.73 Billion | ▲ +210.0% |
| 2014 | 0.08x | ₩724.89 Million | ₩9.07 Billion | — |